| Name | Rosiglitazone hydrochloride |
| Description | Rosiglitazone hydrochloride (BRL-49653 HCl) is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells. |
| In vitro | Bafetinib blocks WT Bcr-Abl autophosphorylation and its downstream kinase activity with IC50 of 11 nM and 22 nM in K562 and 293T cells, respectively. Bafetinib suppresses the growth of the Bcr-Abl-positive cell lines including K562, KU812, and BaF3/wt cells potently without effects on the proliferation of the Bcr-Abl-negative U937 cell line. Moreover, Bafetinib exhibits a dose-dependent antiproliferative effect against Bcr-Abl point mutant cell lines, such as BaF3/E255K cells. [1] In Bcr-Abl+ leukemia cell lines, Bafetinib induces both caspase-mediated and caspase-independent cell death by blocking the phosphorylation of Bcr-Abl. [2] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (25.39 mM), Sonication is recommended.
Ethanol : 73 mg/mL (185.33 mM), Sonication is recommended.
DMSO : 73 mg/mL (185.33 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | TRPVChannel | TRPV Channel | TRPChannel | TRP Channel | Transient receptor potential channels | smoke | senescence | Rosiglitazone Hydrochloride | Rosiglitazone hydrochloride | Rosiglitazone | PPARγ | PPAR | Peroxisome proliferator-activated receptors | ovarian cancer | neuroprotection | mellitus | Inhibitor | inhibit | hepatocellular | HCC | Ferroptosis | diabetic | diabetes | carcinoma | cancer | BRL-49653 | BRL49653 | BRL 49653 | bladder | Autophagy | Apoptosis | antihyperglycemic |
| Inhibitors Related | Stavudine | Aceglutamide | Cysteamine hydrochloride | Hydroxychloroquine | Daidzein | Metronidazole | Guanidine hydrochloride | Paeonol | Naringin | Dimethyl phthalate | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
